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Abstract
Purpose In Trinidad and Tobago (TT), prostate cancer (CaP) is the most commonly diagnosed malignancy and the leading 
cause of cancer deaths among men. TT currently has one of the highest CaP mortality rates in the world.
Methods 6,064 incident and 3,704 mortality cases of CaP occurring in TT from January 1995 to 31 December 2009 reported 
to the Dr. Elizabeth Quamina Cancer population-based cancer registry for TT, were analyzed to examine CaP survival, 
incidence, and mortality rates and trends by ancestry and geography.
Results The age-standardized CaP incidence and mortality rates (per 100,000) based on the 1960 world-standardized in 2009 
were 64.2 and 47.1 per 100,000. The mortality rate in TT increased between 1995 (37.9 per 100,000) and 2009 (79.4 per 
100,000), while the rate in the US decreased from 37.3 per 100,000 to 22.1 per 100,000 over the same period. Fewer African 
ancestry patients received treatment relative to those of Indian and mixed ancestry (45.7%, 60.3%, and 60.9%, respectively).
Conclusions Notwithstanding the limitations surrounding data quality, our findings highlight the increasing burden of CaP 
in TT and the need for improved surveillance and standard of care. Our findings highlight the need for optimized models 
to project cancer rates in developing countries like TT. This study also provides the rationale for targeted screening and 
optimized treatment for CaP to ameliorate the rates we report.
Keywords Cancer in populations of African ancestry · Trinidad and Tobago · Prostate cancer · Caribbean · Geography · 
Cancer incidence · Cancer mortality · Cancer survival
Introduction
With an estimated 1.1  million annual cases diagnosed 
globally in 2012, prostate cancer (CaP) is the second most 
prevalent cancer in men accounting for 15% of the cancers 
diagnosed [1]. Overall, it is the fourth most prevalent cancer 
among men and women and the fifth leading cause of male 
cancer mortality [1]. In parallel with the rate of adoption 
of prostate-specific antigen (PSA) testing and subsequent 
biopsy, there is a 25-fold variation in CaP incidence rates 
globally. Rates are highest in developed countries (e.g., Aus-
tralia/New Zealand and Northern America, age-standardized 
rate (ASR) 111.6 and 97.2 per 100,000, respectively), and 
in less developed regions such as the Caribbean (79.8 per 
100,000) relative to South-Central Asia (4.5 per 100,000) 
where the rates are lowest [1]. Mortality rates are generally 
high in regions with high populations of African descent 
(Caribbean, 29–55 per 100,000 and Sub-Saharan Africa, 
ASRs 19–24 per 100,000), and very low in South-Central 
Asia (2.9 per 100,000) [1].
As in most Caribbean nations, non-communicable dis-
eases (NCDs) including diabetes, cardiovascular disease, 
and cancers represent the largest causes of morbidity and 
mortality. The population of Trinidad and Tobago (TT) in 
2010 was 1,328,019 with a diversity of ancestral groups 
including African (34.2%), East Indian (35.4%), mixed 
(22.8%), unknown (6.2%), and all other ethnic groups 
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(Chinese, White, and Syrian/Lebanese) totaling 1.4% [2]. 
With its petrochemical resources, it is classified as a high-
income country by the World Bank [3], yet a developing 
country by the International Monetary Fund (IMF) [4], and 
is a member of the United Nations Conference of Small 
Island Developing States (SIDS) [5].
TT has a bipartite healthcare system with a public access 
system offering free prescription drugs and other pharma-
ceutical items to all citizens as well as a private system 
where medical services are covered to varying degrees by 
the patient’s private insurance. The Ministry of Health pro-
vides overall healthcare goals and strategic policy to the five 
Regional Health Authorities (RHAs) that manage the public 
health facilities. Each RHA manages public health facilities 
which provide medical services within their catchment areas. 
These services are provided at a ground-level primary care 
approach with local health centers (LHC) (86 in Trinidad 
and 19 in Tobago) and a specialized approach with multi-
specialty serviced hospitals [6]. TT has five RHAs which 
collectively manage four general hospitals, two district hos-
pitals, and four specialist hospitals (psychiatric, maternity, 
thoracic, and a combined radiotherapy/physical medicine/
gerontology facility) [7].
The epidemiological landscape of prostate cancer in TT 
has not been described, despite reports that the CaP mortal-
ity rate in TT is one of the highest in the world [8–10]. Given 
its demographic profile and development status, TT presents 
a unique opportunity to analyze CaP incidence and mortality 
rates and trends relative to more developed countries. We 
present incidence and mortality rates and temporal trends for 
TT from 1995 to 2009 using the most up-to-date data avail-
able from the population-based, National Cancer Registry of 
TT (The Dr. Elizabeth Quamina Cancer Registry). We dis-
cuss disparities by ancestry, age, treatment, and geography 
and their potential impact on survival trends.
Materials and methods
The National Cancer Registry of TT provided de-identified 
cancer surveillance data on 6,064 incident and 3,704 mor-
tality cases of CaP diagnosed in TT from 1 January 1995 to 
31 December 2009. This population-based cancer registry 
was established in 1994 by the Trinidad and Tobago Cancer 
Society, using cancer registry frameworks and policies set 
by the International Agency for Research on Cancer (IARC) 
[11, 12]. The registry uses the CanReg database and statisti-
cal software (version 4.33) to capture incidence and mor-
tality data. The source of the cancer registry records was 
previously described [13]. In brief, the registry abstracts 
cancer surveillance data from both public and private medi-
cal institutions across Trinidad and Tobago including all of 
the main public cancer treatment centers. Abstracted data 
included patients’ home city, age, gender, ancestry, stage, 
grade, and method of cancer detection. All CaP cases were 
classified according to the International Classification of 
Diseases for Oncology (ICD-O) code C61.9 [14]. The record 
selection algorithm is shown in Fig. 1. The incidence and 
mortality cases were merged based on the patient’s regis-
try code, yielding 6,259 records. Three hundred and nine 
records were excluded from the merged datasets resulting in 
an analytic dataset of 5,950 CaP cases. This study received 
IRB approval from the Institutional Review Boards of all 
participating institutions.
The boundaries for the geographic analysis by corpora-
tion and Regional Health Authority (RHA) were previously 
described [13]. The TT Central Statistical Office (CSO) pro-
vided the death certification and population data through the 
2000 and 2010 census. The population pyramids for 2000 
and 2011 were previously described [15, 16]. The CSO col-
lects several population measures including age (single year 
of age, 5- and 10-year age groups), ethnicity, and gender. 
Population estimates for the other study years were calcu-
lated through interpolation using the “irregular points of 
year” estimation method [11, 12].
This cancer registry is the most reliable source of can-
cer surveillance data for the population of TT. The regis-
try collects cancer surveillance records from public and 
private health institutions. Public sector reporting health 
institutions include Port of Spain General Hospital, Caura 
Hospital, National Radiotherapy Centre, Sangre Grande 
Hospital, Tobago Regional Hospital, Mount Hope Wom-
en’s Hospital, Eric Williams Medical Sciences Complex, 
San Fernando Hospital, and Point Fortin Area Hospital. 
Private sector reporting health institutions include Augus-
tus Long Hospital, Petrotrin-Santa Flora Medical Center, 
Incidence dataset Mortality dataset 
Merge
= 6,259 paents
Removed unmatched 
paents
6,064 paents
Removed paents with different 
records for ethnicity in two datasets
6,020 paents
Removed paents in “Other ethnicity” 
group and those with missing RHA
= 5,950 paentsDataset
6,064 paents 3,704 paents
Dataset used for geospaal maps
Fig. 1  Patient selection algorithm
687Cancer Causes & Control (2018) 29:685–697 
1 3
Community Hospital of the Seventh-Day Adventists, Brian 
Lara Treatment Centre, and West Shore Private Hospital.
Imputation by binary logistic regression methodologies 
were used to ascribe ancestry among CaP cancer cases 
with unclassified ancestry [13]. In brief, four separate 
binary logistic regression models were calculated with 
four different ancestral groups which were by far the most 
prevalent in the census data. These were then used as the 
dependent variables (“African,” “Indian,” “Mixed,” and 
“Other: Chinese, White, Syrian/Lebanese”) for estima-
tion purposes. Known demographic variables including 
such factors as gender, age, and corporation of residence 
were used as independent variables in the four predictive 
regression models to assign ancestry based on profiles of 
those cases with available race/ethnicity data. After fit-
ting the four binary logistic regression models for the 
cases with missing race/ethnicity data, probabilities of 
predicted values of the dependent variables (ancestry) 
were calculated. These values showed the probabilities of 
each cancer patient falling into each of the four ances-
tral groups. Cancer patients with unknown race/ethnicity 
were then assigned to one of the four ancestral groups 
according to the highest probability of being a member 
of that group. From the incidence dataset, 1,620 (26.7%) 
cases were imputed with 1,481 and 139 cases imputed to 
African and Indian ancestry, respectively. For the mortal-
ity dataset, 2,132 cases were imputed, with 1,090 and 42 
cases imputed to African and Indian ancestry, respectively.
Statistical analysis
The statistical analysis methods were previously described 
[13]. In brief, we calculated the age-standardized inci-
dence and mortality rates (per 100,000) based on the 1960 
world-standardized [17] and the 2000 United States (US) 
standard population to compare TT CaP rates to global and 
US (Surveillance, Epidemiology, and End Results (SEER) 
Program) rates and trends, respectively. This methodology 
was selected to allow for comparison with the IARC data 
which use the same standardization. The NCI SEER*Stat 
software (version 8.2.1) was used to calculate the 2000 
US age-standardized incidence and mortality rates [18] 
for comparisons to the US data. TT mortality data from 
the World Health Organization (WHO) Cancer Mortality 
Database for the study period [19] were compared to the 
results obtained from analyses based on the TT Cancer 
Registry data.  GraphPad® Prism (GraphPad Software, Inc) 
was used to create the survival curve and compare sur-
vival rates across regions. It uses the method of Kaplan 
and Meier and calculates the 95% confidence interval for 
fractional survival at any particular time.
The mortality‑to‑incidence ratio
The mortality-to-incidence ratio (M/I) was calculated using 
the National Cancer Registry of TT dataset for 1995–2009. 
For comparison, M/I ratios were also calculated using inci-
dence data from GLOBOCAN 2012 and mortality data from 
the WHO Mortality Database for 2012 [19, 20]. The sources 
and quality of these data have been previously described [1, 
21]. The two countries in each WHO region with the maxi-
mal and minimum M/I ratios were included in our analysis 
as well as countries with similar ancestral distributions to 
the TT population. M/I ratios have a maximal value of 1.00, 
which is an indicator of poor survival.
Geospatial mapping
The geospatial maps were rendered in the R computing 
environment [22] using the ggplot command. Locations 
for Trinidad and Tobago were obtained by downloading a 
shapefile from http://www.gadm.org/count ry and plotted 
with the mortality and incidence rates as the fill color.
Results
Prostate cancer statistics
Our analytic dataset consisted of 5,950 CaP cases (78.4% 
of African ancestry, 12.1% of Indian ancestry, and 9.5% of 
mixed ancestry) recorded by the TT Cancer Registry for the 
period between 1 January 1995 and 31 December 2009. In 
TT, prostate cancer accounted for 41.7% of all new cancers 
and 37.4% of all cancer deaths among men (unpublished 
data). Table 1 shows the demographic and clinical charac-
teristics of these incident CaP cases. The mean age at diag-
nosis was 72.6 years, with significant differences by ances-
try. Specifically, CaP patients of Indian ancestry presented 
at a younger age (70.2 years), compared to those of mixed 
(72.3 years) or African ancestry (73 years).
Strikingly, the method of detection was missing in the 
dataset for most cases (57.3%), and only 10.2% of cases were 
initially detected at screening. Overall, a high proportion of 
the staged cases were at the localized stage (40.3%) followed 
by distant (13.1%) and regional (3.2%), with the highest 
frequency of CaP patients diagnosed with localized cancer 
observed among men of Indian ancestry (p < 0.0001). The 
majority of the cases had ‘unspecified’ tumor grade (60.2% 
overall). Across all ancestral groups, a significant proportion 
of the cases were diagnosed as Grade II with less than 1% 
diagnosed as Grade IV.
Overall, the morphology of the majority of CaP cases 
was adenocarcinoma, not otherwise specified (NOS) 
(71.3%). More than 30% of the treatment details were 
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Table 1  Characteristics of 
prostate cancer incident cases 
reported to the TT Cancer 
Registry, overall and by 
ethnicity, 1995–2009
Characteristics Overall African Indian Mixed
Count (%) Count (%) Count (%) Count (%)
Total number of prostate cancer cases 5,950 (–) 4,666 (78.4%) 721 (12.1%) 563 (9.5%)
Age at incidence
 Mean (± SD)* 72.58 (± 10.17) 72.97 (± 10.21) 70.21 (± 10.04) 72.35 (± 9.65)
 ≤ 54 278 (4.7%) 213 (4.6%) 39 (5.4%) 26 (4.6%)
 55–64 980 (16.5%) 740 (15.9%) 154 (21.4%) 86 (15.3%)
 65–74 2,012 (33.8%) 1,509 (32.3%) 303 (42.0%) 200 (35.5%)
 ≥ 75 2,680 (45.0%) 2,204 (47.2%) 225 (31.2%) 251 (44.6%)
Marital status
 Married/common law 2,270 (38.2%) 1,642 (35.2%) 351 (48.7%) 277 (49.2%)
 Single 500 (8.4%) 410 (8.8%) 32 (4.4%) 58 (10.3%)
 Separated/divorced/widowed 576 (9.7%) 421 (9.0%) 85 (11.8%) 70 (12.4%)
 Unspecified 2,604 (43.8%) 2,193 (47.0%) 253 (35.1%) 158 (28.1%)
Geographic area of residence
 Eastern 397 (6.7%) 316 (6.8%) 40 (5.5%) 41 (7.3%)
 North Central 1,118 (18.8%) 844 (18.1%) 136 (18.9%) 138 (24.5%)
 North West 1,795 (30.2%) 1,476 (31.6%) 100 (13.9%) 219 (38.9%)
 South West 1,988 (33.4%) 1,388 (29.7%) 442 (61.3%) 158 (28.1%)
 Tobago 652 (11.0%) 642 (13.8%) 3 (0.4%) 7 (1.2%)
Year of incidence**
 1995–1999 1,736 (29.2%) 1,351 (29.0%) 204 (28.3%) 181 (32.1%)
 2000–2004 2,153 (36.2%) 1,716 (36.8%) 252 (35.0%) 185 (32.9%)
 2005–2009 2,061 (34.6%) 1,599 (34.3%) 265 (36.8%) 197 (35.0%)
Method of detection
 Clinical presentation 1,929 (32.4%) 1,463 (31.4%) 268 (37.2%) 198 (35.2%)
 Screening exam 609 (10.2%) 506 (10.8%) 62 (8.6%) 41 (7.3%)
 Other/unknown/missing 3,412 (57.3%) 2697 (57.8%) 391 (54.2%) 324 (57.5%)
Stage at diagnosis
 In situ/localized 2,397 (40.3%) 1,817 (38.9%) 342 (47.4%) 238 (42.3%)
 Regional 192 (3.2%) 146 (3.1%) 33 (4.6%) 13 (2.3%)
 Distant 778 (13.1%) 590 (12.6%) 82 (11.4%) 106 (18.8%)
 Unstaged 2,583 (43.4%) 2,113 (45.3%) 264 (36.6%) 206 (36.6%)
Grade
 Grade I 711 (11.9%) 529 (11.3%) 104 (14.4%) 78 (13.9%)
 Grade II 1,059 (17.8%) 838 (18.0%) 143 (19.8%) 78 (13.9%)
 Grade III 583 (9.8%) 449 (9.6%) 72 (10.0%) 62 (11.0%)
 Grade IV 15 (0.3%) 10 (0.2%) 4 (0.6%) 1 (0.2%)
 Unspecified 3,582 (60.2%) 2,840 (60.9%) 398 (55.2%) 344 (61.1%)
Morphology***
 Neoplasm, malignant 1,317 (22.1%) 1,076 (23.1%) 129 (17.9%) 112 (19.9%)
 Carcinoma, NOS 317 (5.3%) 257 (5.5%) 33 (4.6%) 27 (4.8%)
 Adenocarcinoma, NOS 4,244 (71.3%) 3,275 (70.2%) 550 (76.3%) 419 (74.4%)
 Other/unknown/missing 72 (1.2%) 58 (1.2%) 9 (1.2%) 5 (0.9%)
Surgery
 Yes 1,287 (21.6%) 957 (20.5%) 191 (26.5%) 139 (24.7%)
 No 2,639 (44.4%) 2,021 (43.3%) 328 (45.5%) 290 (51.5%)
 Unknown/missing 2,024 (34.0%) 1,688 (36.2%) 202 (28.0%) 134 (23.8%)
Chemotherapy
 Yes 332 (5.6%) 224 (4.8%) 57 (7.9%) 51 (9.1%)
 No 3,587 (60.3%) 2,751 (59.0%) 460 (63.8%) 376 (66.8%)
 Unknown/missing 2,031 (34.1%) 1,691 (36.2%) 204 (28.3%) 136 (24.2%)
689Cancer Causes & Control (2018) 29:685–697 
1 3
recorded as unknown, and in cases where treatment details 
were recorded, there were significant differences in the 
receipt of surgical treatment and initiation of chemother-
apy, radiotherapy, hormone therapy, and immunotherapy 
by ancestry. Generally, only 45.7% of African ancestry 
patients received any treatment relative to 60.3% of Indi-
ans and 60.9% of mixed ancestry TT nationals.
We also found that during the study period, there were 
6,064 incident CaP cases for an effective rate of 64.2 per 
100,000 and 3,704 deaths resulting in a mortality rate of 
47.1 per 100,000 in 2009 (Fig. 2a). Given that the WHO 
provides global cancer mortality data, we compared the 
mortality rates calculated using National Cancer Regis-
try of TT data to those reported in the WHO mortality 
database. The data showed that except for 2 years, WHO 
underestimated the rates from 1998 to 2009 (Fig. 2a). In 
fact, for 2009, the most recent year for which data were 
available from the National Cancer Registry of TT, the 
WHO underestimated the ASR mortality rate by 16.9%.
Several metrics of the registry data quality are pro-
vided in Supplementary Table 1. Of note, the percent of 
cases registered only on the basis of the death certificate 
(DCO) fluctuated from 16.55% in 1995 to 30.05% in 2000 
to 17.91% in 2005 and then to 8.44% in 2009. The average 
over the entire period was 23.55%.
Prostate cancer rates in TT relative to the USA
Next, we calculated the TT incidence and mortality ASR 
based on the 2000 US standard population to allow for 
comparisons to US CaP data. The US incidence rate 
decreased from 169.5 per 100,000 in 1995 to 148.6 per 
100,000 in 2009, whereas in TT the rate increased from 
94.8 per 100,000 to 103.6 per 100,000 over the same 
period (Fig.  2b). The mortality rate in TT increased 
between 1995 (37.9 per 100,000) and 2009 (79.4 per 
100,000), while in the US the rate decreased from 37.3 
per 100,000 to 22.1 per 100,000 over the same period 
(Fig. 2c).
Prostate cancer incidence and mortality rates 
by ancestry
Given the demographics of TT, we examined CaP inci-
dence and mortality rates (1960 world-standardized) by 
ancestry (Fig. 2d). Nationals of African ancestry had the 
highest incidence (123.5 per 100,000) and mortality (73.4 
per 100,000), while those of Indian ancestry had the low-
est incidence (29.9 per 100,000) and mortality (15.0 per 
100,000).
Table 1  (continued) Characteristics Overall African Indian Mixed
Count (%) Count (%) Count (%) Count (%)
Radiotherapy
 Yes 582 (9.8%) 388 (8.3%) 108 (15.0%) 86 (15.3%)
 No 2,671 (44.9%) 2,107 (45.2%) 310 (43.0%) 254 (45.1%)
 Unknown/missing 2,697 (45.3%) 2,171 (46.5%) 303 (42.0%) 223 (39.6%)
Hormone therapy
 Yes 1,986 (33.4%) 1,460 (31.3%) 291 (40.4%) 235 (41.7%)
 No 1,934 (32.5%) 1,516 (32.5%) 226 (31.3%) 192 (34.1%)
 Unknown/missing 2,030 (34.1%) 1,690 (36.2%) 204 (28.3%) 136 (24.2%)
Immunotherapy
 Yes 8 (0.1%) 8 (0.2%) 0 (0.0%) 0 (0.0%)
 No 3,908 (65.7%) 2,964 (63.5%) 518 (71.8%) 426 (75.7%)
 Unknown/missing 2,034 (34.2%) 1,694 (36.3%) 203 (28.2%) 137 (24.3%)
Treatment received
 Yes 2,911 (48.9%) 2,133 (45.7%) 435 (60.3%) 343 (60.9%)
 No/unknown 3,039 (51.1%) 2,533 (54.3%) 286 (39.7%) 220 (39.1%)
Vital status
 Mortality 3,423 (57.5%) 2,765 (59.3%) 357 (49.5%) 301 (53.5%)
 Unknown 2,527 (42.5%) 1,901 (40.7%) 364 (50.5%) 262 (46.5%)
Percentages may not sum to 100% due to rounding
*Measures are not counts or percentages
All p values were ≤ 0.0001 except **p = 0.232, and ***p = 0.0209
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Prostate cancer survival rates
Unadjusted Kaplan–Meier curves show that CaP patients 
residing in the NWRHA catchment area had the lowest 
survival probability (5-year survival, 35%; 10-year sur-
vival, 30%) (Fig. 2a). For men in the North Central RHA 
(NCRHA) and Eastern RHA (ERHA), the 5-year survival 
rate was 37% and the 10-year survival rates were 30 and 
32% (Fig. 2e). Interestingly, men in Tobago had the high-
est 5-year (70%) and 10-year (64%) survival probability. 
Unadjusted Kaplan–Meier curves showed that men of 
African ancestry with CaP had the lowest 5-year (42%) 
and 10-year (38%) survival probability, whereas men of 
Indian ancestry had the highest 5-year (50%) and 10-year 
(42%) survival probability (Fig. 2f).
Prostate cancer mortality/incidence ratio
The M/I ratio for TT was calculated using the National 
Cancer Registry of TT dataset for 1995–2009, while those 
for the WHO regions were calculated using incidence data 
from GLOBOCAN 2012 and mortality data from the WHO 
Mortality Database for 2012. In WHO regions, the M/I ratio 
ranged from 0.80 (Africa) to a low of 0.10 (North America) 
with a median value of 0.33 (Fig. 3). The TT M/I ratio was 
0.48 which is higher than that of other countries in the Car-
ibbean, such as Jamaica (0.46) and Barbados (0.37), but 
lower than that of Haiti (0.84) and Dominican Republic 
(0.51). TT had a lower M/I ratio than the highest ratio in all 
WHO regions except North America. Strikingly, when the 
National Cancer Registry of TT rates was used to calculate 
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Fig. 2  Prostate cancer rates, trends, and survival trends, Trinidad and 
Tobago, 1995–2009. a Trends in prostate cancer rates, Trinidad and 
Tobago, 1995–2009. Source: TT Cancer Registry and WHO Cancer 
Mortality Database. Rates are age adjusted to the 1960 world stand-
ard population. b Comparative prostate cancer trend analyses of 
Trinidad and Tobago and USA, 1995–2009: Incidence. Rates are age 
adjusted to the 2000 US standard population. c Comparative prostate 
cancer trend analyses of Trinidad and Tobago and USA, 1995–2009: 
Mortality. Rates are age adjusted to the 2000 US standard popula-
tion. d Prostate cancer incidence and mortality rates in Trinidad and 
Tobago by ancestry, 1995–2009. Rates are age adjusted to the 1960 
world standard population. e Prostate cancer survival probability 
by geography based on residence within Regional Health Authority 
catchment area. f Prostate cancer survival probability by ancestry
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the M/I ratio, the TT ratio became 0.73 (rather than 0.48 as 
reported by WHO) bringing it on par with the M/I ratio of 
Guyana.
Cancer incidence and mortality rates by geography
Geospatial mapping revealed associations between geog-
raphy and TT CaP incidence and mortality rates for 
1995–2009 (Fig. 4). In each RHA, there is at least one 
hospital providing varying levels of oncology services. 
There was significant variation in incidence rates (1960 
world-standardized) between the Regional Health Author-
ities (RHAs) with the highest incidence rates observed 
in the Tobago RHA (TRHA) (156.5 per 100,000) and 
the lowest in ERHA (53.7 per 100,000) and the South 
West RHA (SWRHA) (57.0 per 100,000), respectively. 
The highest incidence rates occurred in Tobago (156.5 
per 100,000), and four of the five corporations with the 
Fig. 3  Prostate cancer mortal-
ity-to-incidence (M/I) rate ratio 
in World Health Organization 
(WHO) regions and select coun-
tries. Data source Incidence: 
Globocan; mortality: WHO 
Mortality database.
 *Data source Trinidad and 
Tobago Cancer Registry
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lowest rates were in the SWRHA. The highest CaP mor-
tality rates (1960 world-standardized) (47.4 per 100,000) 
were reported in the TRHA with the lowest in SWRHA 
(32 per 100,000). The capital city of TT, Port of Spain, had 
the highest mortality (61.8 per 100,000) followed by the 
Borough of Arima (58.7 per 100,000). The five corpora-
tions with the lowest incidence rates also had the lowest 
mortality rates.
Table 2 reports the hazard ratios and confidence interval 
(CI) of CaP mortality by RHA. After adjusting for age, the 
mortality rates in the SWRHA (HR 0.80, 95% CI 0.74–0.87) 
and TRHA (HR 0.49, 95% CI 0.42–0.56) were significantly 
lower than observed in the North West (NWRHA). In mul-
tivariable adjusted models (adjusting for age at incidence, 
marital status, treatment initiation, stage, method of diag-
nosis), CaP mortality rates in the TRHA (HR 0.47, 95% 
Fig. 4  Geospatial maps of prostate cancer incidence and mortality 
rates in Trinidad and Tobago 1995–2009: top panel, left to right—
age-standardized incidence rates for all Regional Health Authorities 
and Corporations, and bottom panel, left to right—age-standardized 
mortality rates for all Regional Health Authorities and Corporations. 
Rates are age adjusted to the 1960 world standard population
Table 2  Hazard ratios (HR) and 95% confidence intervals (CI) of mortality in each Regional Health Authority (RHA) catchment area in TT, 
1995–2009
Statistically significant (p < 0.05) estimates are bolded
*Multivariable models adjusted for age at incidence, marital status, detection method, cancer stage, and treatment (yes/no). The model was 
adjusted for initiation of any treatment
NWRHA ERHA NCRHA SWRHA TRHA
Age adjusted 1.00 (ref) 0.943 (0.822, 1.081) 1.020 (0.929, 1.120) 0.800 (0.737, 0.869) 0.486 (0.419, 0.562)
Multivariable adjusted* 1.00 (ref) 0.900 (0.785, 1.032) 0.953 (0.867, 1.047) 0.956 (0.879, 1.040) 0.469 (0.397, 0.553)
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CI 0.40–0.55) were significantly lower than observed in the 
NWRHA. We next examined differences in RHA mortal-
ity rates by ancestry (Table 3). For all RHAs, after adjust-
ing for age, CaP patients of African ancestry (HR 1.13, 
95% CI 1.01–1.26) had higher mortality rates compared 
to patients of Indian ancestry. In SWRHA, CaP patients of 
African ancestry (HR 1.23, 95% CI 1.05–1.43) had higher 
age-adjusted mortality rates compared to patients of Indian 
ancestry.
Discussion
Our study is the first to analyze and comprehensively 
describe TT CAP incidence, mortality, and survival rates 
and trends from 1995 to 2009. Our findings indicated that 
the CaP burden in TT is high with rates that have been 
increasing over the study period. We identified CaP dispari-
ties by ancestry, geography, and age. The strength of our 
research lies in the analyses of all available cancer registry 
data from 1995 to 2009. Additionally, this is the first geo-
spatial mapping of TT CaP incidence and mortality rates. 
Measuring and understanding the spatial and temporal dis-
tributions of the CaP burden according to geographic area 
in TT is critical for cancer prevention and control initiatives. 
Here we used a geospatial mapping approach that leverages 
CaP incidence and mortality data to identify disparities and 
areas that could benefit from targeted screening.
Our study indicates that the burden of CaP in TT in the 
population of African ancestry is higher than in the other 
ethnic groups. A screening program in Tobago which has 
been in existence for over a decade has identified a high 
prevalence of screening-detected prostate cancer among 
African Tobagonians compared to Asian Indian Tobagoni-
ans [23]. High CaP rates have been reported in black men 
across the African Diaspora including in the US [1, 24–26]. 
In the US, the age-standardized CaP mortality rate for black 
men is 48.2 compared with 9.7 for men overall [27]. The 
majority of the Barbados population share common West 
African heredity with black men in TT and the US albeit 
with low admixture rates [28]. In Barbados, the age-stand-
ardized (US) CaP mortality rate was 62.7 for the period 
1995–2008 [29]. Interestingly, men in TT had an almost 
fourfold higher risk of death than US-born Black men in 
Brooklyn, whereas there was no significant difference in 
the risk of death for Caribbean-born black men in Brooklyn 
compared to US-born black men in the same area [30]. As 
we reported here for TT, it is possible that the CaP rates in 
the African diaspora are also underestimated [31]. This has 
implications for funding as well as cancer prevention and 
control efforts and therefore warrants further study.
The reasons for the higher CaP risk and burden as well 
as poorer outcomes among men of African ancestry are 
Table 3  Hazard ratios (HR) 
and 95% confidence intervals 
(CI) of mortality (B) in each 
Regional Health Authority 
(RHA) catchment area in TT, by 
ancestry, 1995–2009
Statistically significant (p < 0.05) estimates are bolded
* Multivariable models adjusted for age at incidence, marital status, detection method, cancer stage, and 
treatment (yes/no). The model was adjusted for initiation of any treatment
Ancestry
Indian Mixed African
All RHA
 Age adjusted 1.00 (ref) 1.008 (0.865, 1.176) 1.129 (1.011, 1.261)
 Multivariable adjusted* 1.00 (ref) 1.030 (0.883, 1.202) 1.022 (0.914, 1.142)
Eastern RHA
 Age adjusted 1.00 (ref) 0.680 (0.367, 1.258) 1.046 (0.671, 1.631)
 Multivariable adjusted* 1.00 (ref) 0.871 (0.467, 1.625) 0.998 (0.636, 1.567)
North Central RHA
 Age adjusted 1.00 (ref) 0.897 (0.657, 1.225) 1.012 (0.798, 1.283)
 Multivariable adjusted* 1.00 (ref) 1.011 (0.738, 1.385) 1.007 (0.793, 1.279)
North West RHA
 Age adjusted 1.00 (ref) 0.986 (0.723, 1.346) 1.197 (0.919, 1.561)
 Multivariable adjusted* 1.00 (ref) 1.055 (0.772, 1.441) 1.074 (0.823, 1.402)
South West RHA
 Age adjusted 1.00 (ref) 0.999 (0.765, 1.304) 1.226 (1.047, 1.435)
 Multivariable adjusted* 1.00 (ref) 1.089 (0.833, 1.423) 1.144 (0.977, 1.341)
Tobago RHA
 Age adjusted 1.00 (ref) 0.301 (0.019, 4.811) 0.845 (0.118, 6.039)
 Multivariable adjusted* 1.00 (ref) 0.077 (0.005, 1.308) 0.516 (0.069, 3.879)
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unclear. It is clear from our findings that men of African 
ancestry have the highest percentage of unstaged and the 
lowest percent diagnosed at a localized stage or Grade I. 
Additionally, we report that men of African ancestry are 
least likely to have received some form of treatment. These 
disparities are likely driven by deficiencies in the health 
care system, health-seeking behaviors and differences in 
the genomic background of CaP among different ancestries. 
Genetic studies have identified variants that confer increased 
CaP risk in people of African ancestry [32, 33]. Given the 
high CaP mortality rates in TT, there is need for genomic 
sequencing to identify clinically actionable genomic insults 
that can inform a CaP precision medicine framework [34]. 
Some studies have identified genomic alterations of prog-
nostic clinical significance [35, 36]. Our study highlights 
the need to determine the genomic landscape of CaP in TT 
to ascertain whether ancestry-specific genetic insults might 
play a role in the disparities we report.
Given the higher rate of CaP among men of African 
ancestry that we report, it might be worthwhile to look at 
screening approaches in TT. Prior to 2001–2002, the PSA 
test was not readily available, increasing the risk that most 
men would present with advanced disease (unpublished 
data). In 2002, when it became available, there was reluc-
tance by men in Trinidad to seek testing (unpublished data). 
This situation was different in Tobago where intensive, pop-
ulation-based, opportunistic screening efforts occurred [23, 
25]. These studies reported a CaP prevalence about three to 
four times greater than rates reported from similar screen-
ing studies of predominantly Caucasian populations (ages 
50–79 years) [25, 37–39]. Interestingly, in the same study, 
12% of biopsied men aged 40–49 years were diagnosed with 
prostate cancer [25]. There is a need for the development 
of evidence-based screening guidelines specific to TT. The 
screening guidelines offered by United States Preventive 
Services Task Force [40], American Cancer Society [41], 
and the American Urological Association [42] are conflict-
ing, derived from studies conducted with relatively few men 
of African ancestry.
A recent representative survey in TT reported that of 
1,093 men only 28.6% and 46.6% of men in the 45–54 and 
55–64 age groups, respectively, had a prostate examina-
tion [43]. This report might help to explain the fact that 
men in TT are diagnosed at more advanced ages than in 
several other countries. In TT, the mean age of diagnosis 
was 72.6 years, whereas a recent study reported 62 years 
for Americans, 66 years for Asian Indians, 69 years for 
Senegalese cases, and 68  years in Barbados [29, 44]. 
The advanced age of presentation suggests that the high 
percent of unstaged and ungraded cancers we report are 
likely those of men with advanced disease. Typically, men 
are less likely to present for medical advice, screening, 
and follow-up care even when faced with symptoms that 
deserve such attention [45, 46]. Layering this, in TT there 
are health-avoidant behaviors and attitudes such as the use 
of complementary and alternative medicine prior to seek-
ing medical attention. In fact, 87% of respondents in a 
recent TT survey reported that herbal remedies had either 
equal or greater efficacy compared with conventional pre-
scribed medicines [47]. This delay potentially results in 
patients presenting at a more advanced stage with a higher 
possibility of metastases. The reasons for the advanced 
age of presentation and the impact on clinical features are 
worthy of further study.
We report a high burden of CaP in TT along with gaps 
in the data on stage, grade, method of detection, and treat-
ment. This suggests that there is need for more focused 
attention to ameliorate the trends we report. Given the 
high cost of treating CaP, there is need for stakeholders in 
the health sector to launch a national prostate awareness 
campaign to increase the awareness of prostate cancer, 
early detection, and prevention efforts aimed at modifi-
able risk factors such as smoking, proper exercise, and 
good nutrition.
There are several limitations inherent in this study. 
These results might reflect an underestimation of CaP 
rates as all cases are not systematically reported to the 
National Cancer Registry of TT as is required by law in the 
USA. Cancer surveillance via the population-based regis-
try plays a critical function in formulating and monitoring 
the success of cancer control plans [48, 49]. Steps towards 
surveillance improvements in TT might include surveys 
and hospital chart reviews to quantify the level of under-
notification as a first step towards improving the system. 
It is possible that some of the increase in prostate cancer 
mortality rates over the study period could be attributed 
to improvements in data quality by the registry. This pos-
sibility again highlights the need to improve cancer sur-
veillance in TT. Additionally, neither the lack of informa-
tion about measures of data quality by geographical area, 
nor case ascertainment by geographical area, makes any 
interpretation of the spatial patterns problematic. If report-
ing these geographical results in the abstract, it should be 
accompanied by a statement regarding the limited data 
quality and unknown impact on the variation. Further, 
a substantial number of cases were unstaged or had an 
unknown grade. Additionally, since ancestry was primar-
ily self-reported or imputed in the absence of admixture 
analysis, the ancestry of all cases were not validated. 
The average DCO cases of 23.55% is slightly above the 
threshold set by IARC for inclusion in Cancer Incidence 
in Five Continents [50]. Taken together, these limitations 
can impact data quality and the interpretation of observed 
patterns and thus reflects a need for the TT cancer registry 
to improve data quality.
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Conclusion
Despite these limitations, the strength of this study lies in 
the analyses of all of the currently available CaP data col-
lected from 1995 to 2009 in TT. We showed that there are 
associations by ancestry, geography, and age with respect 
to CaP incidence and mortality rates and trends in TT. 
Despite its status as a high-income country with universal 
healthcare access, the mortality rate in TT is one of the 
highest in the world. Our findings highlight the need for 
targeted screening and improved clinical approaches to 
ameliorate these high rates of CaP mortality. A key find-
ing from this study is the urgent need for a more robust 
population-based cancer registry in Trinidad and Tobago 
as a first step towards reducing the burden we report.
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